Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 J&J Looks to Buy Out Crucell | Contract Pharma

What are you searching for?

Sign in
Breaking News

J&J Looks to Buy Out Crucell

Johnson & Johnson and Crucell have entered negotiations to discuss J&J’s potential purchase of all outstanding shares of Crucell for approximately $2.3 billion in cash.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Johnson & Johnson and Crucell have entered negotiations to discuss J&J’s potential purchase of all outstanding shares of Crucell for approximately $2.3 billion in cash. J&J, through an affiliate, currently holds approximately 18% of Crucell shares and has submitted a statement to the U.S. SEC related to its change in investment intent with respect to Crucell.

This potential transaction would combine Crucell’s expertise in the manufacture, discovery and commercialization of vaccines with J&J’s experience in the development and marketing of pharmaceutical products, as well as its strong platform in the vaccine market. Should the transaction occur, J&J expects to maintain Crucell’s existing facilities and to retain its senior management and current employment levels. Crucell would serve as the center for vaccines within the J&J pharmaceutical group.

The transaction remains subject to negotiation of terms of a definitive agreement and internal approvals of J&J management and the management and supervisory boards of Crucell.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters